NCT02825940View on ClinicalTrials.gov

A Study to Assess the Pharmacokinetics, Efficacy, and Safety of Atezolizumab Administered Intravenously (IV) as a Single Agent or in Combination With Chemotherapy in Chinese Participants With Locally Advanced or Metastatic Solid Tumors

PHASE1CompletedINTERVENTIONAL
Enrollment

120

Participants

Timeline

Start Date

August 4, 2016

Primary Completion Date

January 14, 2020

Study Completion Date

November 4, 2022

Conditions
Neoplasms
Interventions
DRUG

Atezolizumab

Atezolizumab will be administered at a dose of 1200 mg IV q3w (in 21-day cycles), except for participants with NSCLC who will be administered atezolizumab at a dose of 1200 mg IV on Day 1.

DRUG

Gemcitabine

Gemcitabine will be administered to participants with NSCLC at a dose of 1250 mg/m\^2 on Days 1 and 8.

DRUG

Cisplatin

Cisplatin will be administered to participants with NSCLC at a dose of 75 mg/m\^2 on Day 1.

Trial Locations (7)

100142

Beijing Cancer Hospital, Beijing

132013

Jilin Cancer Hospital, Changchun

150081

Harbin Medical University Cancer Hospital, Harbin

200032

Zhongshan Hospital Fudan University, Shanghai

200120

Fudan University Shanghai Cancer Center, Shanghai

310018

Sir Run Run Shaw Hospital, Hangzhou

510060

Cancer Center, Sun Yat-sen University of Medical Sciences; Department of Medical Oncology, Guangzhou

All Listed Sponsors
lead

Hoffmann-La Roche

INDUSTRY

NCT02825940 - A Study to Assess the Pharmacokinetics, Efficacy, and Safety of Atezolizumab Administered Intravenously (IV) as a Single Agent or in Combination With Chemotherapy in Chinese Participants With Locally Advanced or Metastatic Solid Tumors | Biotech Hunter | Biotech Hunter